Underlying Biological Mechanisms
Neuroblastoma occurs when immature nerve cells, known as neuroblasts, grow out of control instead of maturing into functioning nerve cells. These cells undergo genetic mutations that allow them to multiply rapidly and form tumors. While researchers have identified specific genetic changes, such as the amplification of the MYCN gene, the exact reason why these initial mutations occur remains largely unknown. In most cases, these gene changes are acquired early in fetal development or infancy and are not inherited from parents.
Risk Factors and Triggers
The primary risk factor for neuroblastoma is age, as it is most common in infants and very young children. A family history of neuroblastoma is a risk factor but is extremely rare, accounting for only a small percentage of cases. Congenital anomalies or birth defects have been associated with a slightly higher risk in some studies, but for the vast majority of children, there are no known lifestyle or environmental triggers such as maternal diet, smoking, or chemical exposure during pregnancy that have been definitively linked to the disease.
Prevention Strategies
Currently, there are no known ways to prevent neuroblastoma because the risk factors are generally not related to lifestyle or environment. Since the majority of cases arise from random genetic changes during early development, parents cannot prevent the disease through behavioral changes. Strategies focus on early detection and reducing the severity of the disease through appropriate risk stratification and treatment rather than primary prevention.

Clinically Meaningful Signs and Symptoms
Symptoms of neuroblastoma vary greatly depending on where the tumor is located, how large it is, and whether it has spread. The most common sign is a lump or swelling in the abdomen that does not hurt but may cause the belly to look swollen. Tumors in the chest or neck might cause breathing trouble, persistent coughing, or a drooping eyelid with a small pupil. If the cancer has spread to the bones, children may experience bone pain, limping, or refusal to walk. Dark circles or bruising around the eyes, often resembling "raccoon eyes," can indicate the disease has spread to the skull area. Other general symptoms include fever, unexplained weight loss, and irritability. Some tumors secrete hormones that cause high blood pressure, rapid heartbeat, or watery diarrhea.
Diagnostic Tests and Exams
Clinicians use a combination of exams and tests to diagnose neuroblastoma. Blood and urine tests are used to check for elevated levels of catecholamines (hormones like HVA and VMA) which are produced by the neuroblastoma cells. Imaging tests such as ultrasound, CT scans, or MRI scans help visualize the tumor's location and size. A specific scan called an MIBG scan involves injecting a small amount of radioactive material that attaches to neuroblastoma cells, highlighting them in images. To confirm the diagnosis, a biopsy is performed where a sample of the tumor or bone marrow is removed and examined under a microscope.
Differential Diagnosis
Neuroblastoma can be confused with other childhood conditions that cause abdominal masses or similar symptoms. These include Wilms tumor (a type of kidney cancer), lymphoma, rhabdomyosarcoma, or benign conditions like infection or bruising from trauma. Accurate diagnosis through biopsy and specific urine markers is essential to distinguish it from these other conditions.

Treatment Options
Treatment for neuroblastoma depends on the risk group assigned to the child—low, intermediate, or high. Surgery is often the first step to remove as much of the tumor as possible. For low-risk cases, surgery alone or even observation may be sufficient, as some tumors in infants can disappear on their own. Intermediate and high-risk cases typically require chemotherapy to kill cancer cells and shrink tumors. Radiation therapy may be used to target remaining cancer cells after other treatments. High-risk neuroblastoma often involves a more intensive regimen including high-dose chemotherapy followed by a stem cell transplant to replace blood-forming cells destroyed by the treatment. Immunotherapy, such as dinutuximab, is a modern treatment used in high-risk cases to help the body's immune system recognize and destroy cancer cells. Retinoid therapy is also used to help stop cancer cells from growing.
Management and Monitoring
Ongoing management involves regular follow-up visits to monitor for recurrence and manage side effects. Long-term follow-up is crucial because treatments can affect growth, hearing, and organ function. Supportive care includes managing nutrition, pain, and infection risk during intensive therapy. Effectiveness varies; low-risk groups have very high cure rates, while high-risk groups require aggressive multimodal therapy to improve outcomes.
When to Seek Medical Care
Parents should consult a doctor if they notice any unexplained lumps or swelling in their child's abdomen or neck, persistent changes in walking or coordination, or unexplained bruising around the eyes. Immediate medical attention is needed if a child has difficulty breathing, severe pain, or signs of spinal cord compression such as weakness in the legs or loss of bladder control. Routine well-child visits are important for monitoring general health, but specific symptoms like persistent fever or bone pain warrant a dedicated evaluation.

Severity and Disease Course
Neuroblastoma is classified into risk groups (low, intermediate, and high) which determine severity. Low-risk neuroblastoma, common in infants, is often less severe and may even regress spontaneously without extensive treatment. High-risk neuroblastoma is a serious, aggressive condition that has often spread (metastasized) by the time of diagnosis and requires intensive treatment. The disease course can last for months to years depending on the response to therapy. Remission is the goal, but recurrence is a risk, particularly in high-risk patients within the first few years after treatment.
Prognosis and Factors Influencing Outcomes
The prognosis varies significantly based on the child's age, the stage of the cancer, and the biology of the tumor (such as MYCN gene amplification). Infants younger than 18 months generally have a better outlook than older children. Children with low-risk disease have excellent survival rates, often exceeding 95%. High-risk neuroblastoma is more challenging to cure, with survival rates historically lower, though modern immunotherapy has improved these outcomes. Early diagnosis and the absence of unfavorable genetic markers are positive prognostic factors.
Complications and Long-Term Effects
Short-term complications include infection, bleeding, and fatigue from chemotherapy. Long-term effects, known as late effects, can result from the disease or its treatment. These may include hearing loss, kidney problems, heart issues, hormonal imbalances affecting growth and fertility, and a slightly increased risk of secondary cancers later in life. Regular long-term monitoring is essential to detect and manage these potential issues early.

Impact on Daily Activities and School
During active treatment, a child's daily life is significantly altered by frequent hospital stays, clinic visits, and side effects like fatigue or nausea. Attending school or daycare may not be possible due to a weakened immune system, requiring home-bound instruction or tutoring. Social interaction with peers might be limited, which can impact social development. As recovery progresses, reintegrating into school requires planning for potential learning delays or physical limitations.
Emotional and Mental Health
A neuroblastoma diagnosis affects the entire family. Children may experience anxiety, fear of medical procedures, or behavioral regression. Parents and siblings often deal with high levels of stress, uncertainty, and emotional exhaustion. Coping strategies include maintaining a routine when possible, utilizing child life specialists in hospitals to explain procedures in age-appropriate ways, and seeking counseling or support groups for the whole family.
Questions to Ask Your Healthcare Provider

• What is the risk group for my child and what does that mean for our treatment plan?
• What are the specific side effects of the proposed treatments, and which ones might be permanent?
• How will this diagnosis and treatment affect my child's growth and development?
• Are there any clinical trials available that would be appropriate for my child?
• What signs or symptoms indicate an emergency that requires immediate care?
• What is the schedule for follow-up scans and tests after treatment ends?

Q: Is neuroblastoma hereditary?
A: In the vast majority of cases, neuroblastoma is not inherited. Only about 1% to 2% of cases are familial, meaning they are passed down in families. Most cases result from random genetic changes that happen during fetal development.
Q: Can neuroblastoma go away on its own?
A: Yes, in some specific cases. Certain infants with a special stage of the disease (often called stage MS or 4S) may have tumors that shrink and disappear spontaneously without chemotherapy or surgery, though they are still closely monitored.
Q: What are the chances of survival?
A: Survival rates depend heavily on the risk group. Children with low-risk neuroblastoma have a survival rate of over 95%. The survival rate for high-risk neuroblastoma is lower, generally around 50% to 60%, but statistics are improving with newer treatments like immunotherapy.
Q: Is there a screening test for neuroblastoma?
A: There is no routine screening test recommended for the general population. While urine tests can detect the disease, studies have shown that mass screening does not reduce the number of deaths in older children with advanced disease and may lead to unnecessary treatment for tumors that would have resolved on their own.
Q: Does neuroblastoma affect adults?
A: It is extremely rare for neuroblastoma to be diagnosed in adults. It is primarily a cancer of early childhood, with most cases diagnosed before age 5.